IS8669A - Rasagilínlyfjablöndur sem einsleitni innihaldsefna hefur verið endurbætt í - Google Patents

Rasagilínlyfjablöndur sem einsleitni innihaldsefna hefur verið endurbætt í

Info

Publication number: IS8669A
Authority: IS; Iceland
Prior art keywords: homogeneity; ingredients; improved; rasagiline formulations; rasagiline
Prior art date: 2005-02-23

Application number

IS8669A

Other languages

English (en)

Inventor

Berger Peskin Tirtza

Original Assignee

Teva Pharmaceutical Industries, Ltd.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-02-23

Filing date

2007-08-15

Publication date

2007-08-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36927751&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS8669(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2007-08-15 Application filed by Teva Pharmaceutical Industries, Ltd. filed Critical Teva Pharmaceutical Industries, Ltd.

2007-08-15 Publication of IS8669A publication Critical patent/IS8669A/is

Links

238000009472 formulation Methods 0.000 title 1
239000004615 ingredient Substances 0.000 title 1
239000000203 mixture Substances 0.000 title 1
RUOKEQAAGRXIBM-GFCCVEGCSA-N rasagiline Chemical compound C1=CC=C2[C@H](NCC#C)CCC2=C1 RUOKEQAAGRXIBM-GFCCVEGCSA-N 0.000 title 1
229960000245 rasagiline Drugs 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Psychology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

IS8669A 2005-02-23 2007-08-15 Rasagilínlyfjablöndur sem einsleitni innihaldsefna hefur verið endurbætt í IS8669A (is)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US65562205P	2005-02-23	2005-02-23
US72090805P	2005-09-27	2005-09-27
PCT/US2006/006252 WO2006091657A1 (en)	2005-02-23	2006-02-22	Rasagiline formulations of improved content uniformity

Publications (1)

Publication Number	Publication Date
IS8669A true IS8669A (is)	2007-08-15

Family

ID=36927751

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IS8669A IS8669A (is)	2005-02-23	2007-08-15	Rasagilínlyfjablöndur sem einsleitni innihaldsefna hefur verið endurbætt í

Country Status (15)

Country	Link
US (1)	US7815942B2 (is)
EP (1)	EP1848402B2 (is)
JP (2)	JP5738509B2 (is)
KR (5)	KR20130129300A (is)
AU (1)	AU2006216696B2 (is)
BR (1)	BRPI0608209A2 (is)
CA (2)	CA2600011C (is)
ES (1)	ES2586412T5 (is)
IL (2)	IL184033A0 (is)
IS (1)	IS8669A (is)
MX (1)	MX2007010233A (is)
NO (1)	NO20074823L (is)
NZ (1)	NZ560660A (is)
RU (1)	RU2404746C2 (is)
WO (1)	WO2006091657A1 (is)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5744500A (en) *	1990-01-03	1998-04-28	Teva Pharmaceutical Industries, Ltd.	Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
SI1567152T1 (sl)	2002-11-15	2013-10-30	Teva Pharmaceutical Industries Ltd.	Uporaba rasagilina z riluzolom za zdravljenje amiotrofične lateralne skleroze
US20060018957A1 (en) *	2004-07-26	2006-01-26	Lerner E I	Pharmaceutical dosage forms including rasagiline
ES2371883T3 (es) *	2004-11-24	2012-01-11	Teva Pharmaceutical Industries Ltd.	Composiciones de rasagilina de disgregación oral.
US20060172942A1 (en) *	2005-02-02	2006-08-03	Teva Pharmaceutical Industries, Ltd.	Process for producing polypeptide mixtures using hydrogenolysis
RS52867B (sr) *	2005-02-17	2013-12-31	Teva Pharmaceutical Industries Ltd.	Kombinovana terapija glatiramer acetatom i razagilinom za lečenje multiple skleroze
US7815942B2 (en)	2005-02-23	2010-10-19	Teva Pharmaceutical Industries, Ltd.	Rasagiline formulations of improved content uniformity
US7491847B2 (en) *	2005-11-17	2009-02-17	Teva Pharmaceutical Industries, Ltd.	Methods for isolating propargylated aminoindans
US7572834B1 (en)	2005-12-06	2009-08-11	Teva Pharmaceutical Industries, Ltd.	Rasagiline formulations and processes for their preparation
US8809310B2 (en)	2006-02-21	2014-08-19	Teva Pharmaceutical Industries, Ltd.	Use of rasagiline for the treatment of multiple system atrophy
AU2007235517B2 (en)	2006-04-03	2013-01-31	Teva Pharmaceutical Industries, Ltd.	Use of rasagiline for the treatment of Restless Legs Syndrome
EP1892233A1 (de)	2006-08-18	2008-02-27	Ratiopharm GmbH	Neue Salze des Wirkstoffs Rasagilin
UA97382C2 (ru) *	2006-12-14	2012-02-10	Тева Фармасьютікл Індастріз, Лтд.	Таннат разагилина
AU2007334428B2 (en) *	2006-12-14	2014-05-29	Teva Pharmaceutical Industries, Ltd.	Crystalline solid rasagiline base
EP1987816A1 (de) *	2007-04-30	2008-11-05	Ratiopharm GmbH	Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff
US20090062400A1 (en) *	2007-09-05	2009-03-05	Laurence Oron	Method of treating glaucoma using rasagiline
US8188149B2 (en) *	2007-09-17	2012-05-29	Teva Pharmaceutical Industries, Ltd.	Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss
EA201070842A1 (ru) *	2008-01-11	2011-04-29	Тева Фармасьютикал Индастриз, Лтд.	Препаративные формы разагилина, их получение и применение
WO2009122301A2 (en) *	2008-03-31	2009-10-08	Actavis Group Ptc Ehf	Rasagiline mesylate particles and process for the preparation thereof
AU2009258120B2 (en) *	2008-06-10	2014-11-27	Teva Pharmaceutical Industries, Ltd.	Rasagiline soft gelatin capsules
EP2296462A4 (en) *	2008-06-13	2011-06-15	Teva Pharma	RASAGILINE FOR INFLUENCING MORBUS PARKINSON
JP2011525489A (ja)	2008-06-19	2011-09-22	テバファーマシューティカルインダストリーズリミティド	ラサリジン塩基の精製方法
NZ589547A (en)	2008-06-19	2013-03-28	Teva Pharma	Dried rasagiline base having a water content less than 0.5 % by weight
EP2657221A1 (en) *	2008-11-20	2013-10-30	Dr. Reddy's Laboratories Ltd.	Preparation of rasagiline and salts thereof
DE102008064061A1 (de)	2008-12-19	2010-06-24	Ratiopharm Gmbh	Feste Zusammensetzung mit dem Wirkstoff Rasagilin
US20100189790A1 (en) *	2009-01-23	2010-07-29	Teva Pharmaceutical Industries, Ltd.	Delayed release rasagiline formulation
WO2010100219A2 (en)	2009-03-05	2010-09-10	Sandoz Ag	Pharmaceutical composition containing 1h-inden-1-amine, 2,3-dihydro-n-2-propynyl-, (1r)-, methanesulfonate
WO2010111264A2 (en) *	2009-03-24	2010-09-30	Dr. Reddy's Laboratories Ltd.	Rasagiline formulations
PT2451771E (pt)	2009-07-09	2014-09-19	Ratiopharm Gmbh	Sais de rasagilina e suas preparações farmacêuticas
US8741962B2 (en)	2009-11-26	2014-06-03	Usv Limited	Process for preparation of Rasagiline and salts thereof
WO2011092717A2 (en) *	2010-02-01	2011-08-04	Alkem Laboratories Ltd.	Rasagiline mesylate having large particle size and a process for preparation thereof
ES2607806T5 (es) *	2010-02-12	2024-10-07	Pfizer	Sales y polimorfos de 8-fluoro-2-{4-[(metilamino}metil]fenil}-1,3,4,5-tetrahidro-6H-azepino[5,4,3-cd]indol-6-ona
JP5820469B2 (ja)	2010-04-30	2015-11-24	テイコクファーマユーエスエーインコーポレーテッド	プロピニルアミノインダンの経皮組成物
EP2389927A1 (en)	2010-05-30	2011-11-30	Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi	Pharmaceutical formulations of rasagiline
RU2587330C2 (ru)	2010-07-27	2016-06-20	Тева Фармасьютикал Индастриз Лтд.	Применение разагилина для лечения обонятельной дисфункции
WO2012015946A1 (en)	2010-07-27	2012-02-02	Teva Pharmaceutical Industries Ltd.	Dispersion of rasagiline citrate
EP2688561B1 (en)	2011-03-24	2018-08-22	Teikoku Pharma USA, Inc.	Transdermal compositions comprising an active agent layer and an active agent conversion layer
WO2012153349A2 (en)	2011-05-04	2012-11-15	Cadila Healthcare Limited	Rasagiline and its pharmaceutically acceptable salts
CA2851433A1 (en)	2011-10-10	2013-04-18	Teva Pharmaceutical Industries Ltd.	R(+)-n-methyl-propargyl-aminoindan
BR112014008555A2 (pt)	2011-10-10	2017-04-18	Teva Pharma	r(+)-n-formil-propargil-aminoindano
EP2776020B1 (en)	2011-11-09	2019-09-11	Teikoku Seiyaku Co., Ltd.	Methods for the treatment of skin neoplasms
EP2610239A1 (en)	2012-01-02	2013-07-03	Dr. Reddy's Laboratories Ltd.	Preparation Of Rasagiline Hemitartrate
WO2013139387A1 (en)	2012-03-21	2013-09-26	Synthon Bv	Stabilized pharmaceutical compositions comprising rasagiline salts
AR092168A1 (es)	2012-08-17	2015-03-25	Teva Pharma	Formulaciones parenterales de rasagilina
JP6050896B2 (ja)	2012-11-02	2016-12-21	テイコクファーマユーエスエーインコーポレーテッド	プロピニルアミノインダン経皮組成物
JP2016514162A (ja)	2013-03-14	2016-05-19	テバファーマシューティカルインダストリーズリミティド	ラキニモドナトリウムの結晶およびその製造のための改善された方法
EP3538071B1 (en)	2016-11-10	2022-09-14	Medisca Pharmaceutique Inc.	Pharmaceutical compounding methods and systems

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3513249A (en) *	1968-12-24	1970-05-19	Ideal Ind	Explosion connector with improved insulating means
GB8914804D0 (en) *	1989-06-28	1989-08-16	Glaxo Group Ltd	Process
IL92952A (en)	1990-01-03	1994-06-24	Teva Pharma	R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
US5744500A (en)	1990-01-03	1998-04-28	Teva Pharmaceutical Industries, Ltd.	Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
US5844003A (en) *	1991-04-04	1998-12-01	Innovations Foundation	Use of deprenyl compounds to maintain, prevent loss, or recover nerve cell function
US5767164A (en) *	1991-04-04	1998-06-16	Innovations Foundation	Use of deprenyl to rescue damaged nerve cells
US5444095A (en) *	1991-04-04	1995-08-22	University Of Toronto, Innovations Foundation	Use of deprenyl to rescue damaged nerve cells
IL99759A (en)	1991-10-16	1997-06-10	Teva Pharma	Mono-fluorinated derivatives of n-propargyl-1-aminoindan, their preparation and pharmaceutical compositions containing them
IL111240A (en) *	1993-10-18	2001-10-31	Teva Pharma	Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them
EP0738149B1 (en)	1994-01-10	2006-11-29	Teva Pharmaceutical Industries, Ltd.	1-aminoindan derivatives and compositions thereof
IL115357A (en)	1995-09-20	2000-01-31	Teva Pharma	Stable compositions containing N-propargyl-1-aminoindan and polyhydric alcohols
IL118836A (en)	1996-07-11	2001-01-11	Teva Pharma	Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan
CA2275425C (en)	1996-12-18	2009-08-04	Michael Chorev	Aminoindan derivatives
WO1999037293A2 (en) *	1998-01-27	1999-07-29	Thomas Thomas N	Use of an mao-a or mao-b inhibitor for the treatment of vascular disorders
US7766013B2 (en) *	2001-06-05	2010-08-03	Alexza Pharmaceuticals, Inc.	Aerosol generating method and device
BR0211317A (pt)	2001-07-04	2004-12-14	Sun Pharmaceutical Ind Ltd	Sistema para a liberação controlada de uma droga por meio de retenção gástrica
US20040052843A1 (en) *	2001-12-24	2004-03-18	Lerner E. Itzhak	Controlled release dosage forms
US20040010038A1 (en) *	2002-02-27	2004-01-15	Eran Blaugrund	Propargylamino indan derivatives and propargylamino tetralin derivatives as brain-selective MAO inhibitors
AU2003219913A1 (en)	2002-02-27	2003-09-09	Teva Pharmaceutical Industries, Ltd.	Propargylamino indan derivatives and propargylamino tetralin derivatives as brain-selective mao inhibitors
SI1567152T1 (sl)	2002-11-15	2013-10-30	Teva Pharmaceutical Industries Ltd.	Uporaba rasagilina z riluzolom za zdravljenje amiotrofične lateralne skleroze
WO2004112799A1 (en) *	2003-06-13	2004-12-29	Chrysalis Technologies Incorporated	Methods and apparatus for producing nanoscale particles
US20050026979A1 (en)	2003-07-31	2005-02-03	Maha Ghazzi	Methods for treating inflammation and inflammation-associated diseases with a statin and ether
US7735024B2 (en) *	2003-10-29	2010-06-08	Intel Corporation	Methods and apparatus to provide a handheld pointer-based user interface
US20060018957A1 (en) *	2004-07-26	2006-01-26	Lerner E I	Pharmaceutical dosage forms including rasagiline
WO2006057912A2 (en)	2004-11-24	2006-06-01	Teva Pharmaceutical Industries, Ltd.	Rasagiline orally disintegrating compositions
ES2371883T3 (es) *	2004-11-24	2012-01-11	Teva Pharmaceutical Industries Ltd.	Composiciones de rasagilina de disgregación oral.
US7815942B2 (en)	2005-02-23	2010-10-19	Teva Pharmaceutical Industries, Ltd.	Rasagiline formulations of improved content uniformity
US7491847B2 (en) *	2005-11-17	2009-02-17	Teva Pharmaceutical Industries, Ltd.	Methods for isolating propargylated aminoindans
US7572834B1 (en) *	2005-12-06	2009-08-11	Teva Pharmaceutical Industries, Ltd.	Rasagiline formulations and processes for their preparation
US8809310B2 (en)	2006-02-21	2014-08-19	Teva Pharmaceutical Industries, Ltd.	Use of rasagiline for the treatment of multiple system atrophy
AU2007235517B2 (en)	2006-04-03	2013-01-31	Teva Pharmaceutical Industries, Ltd.	Use of rasagiline for the treatment of Restless Legs Syndrome
EP1892233A1 (de)	2006-08-18	2008-02-27	Ratiopharm GmbH	Neue Salze des Wirkstoffs Rasagilin
AU2007334428B2 (en)	2006-12-14	2014-05-29	Teva Pharmaceutical Industries, Ltd.	Crystalline solid rasagiline base
UA97382C2 (ru) *	2006-12-14	2012-02-10	Тева Фармасьютікл Індастріз, Лтд.	Таннат разагилина
EP1987816A1 (de)	2007-04-30	2008-11-05	Ratiopharm GmbH	Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff
EA201070842A1 (ru) *	2008-01-11	2011-04-29	Тева Фармасьютикал Индастриз, Лтд.	Препаративные формы разагилина, их получение и применение

2006
- 2006-02-22 US US11/359,324 patent/US7815942B2/en active Active
- 2006-02-22 NZ NZ560660A patent/NZ560660A/en not_active IP Right Cessation
- 2006-02-22 KR KR1020137025486A patent/KR20130129300A/ko not_active Ceased
- 2006-02-22 KR KR1020177004882A patent/KR20170023211A/ko not_active Ceased
- 2006-02-22 MX MX2007010233A patent/MX2007010233A/es active IP Right Grant
- 2006-02-22 KR KR1020187006228A patent/KR20180026580A/ko not_active Ceased
- 2006-02-22 JP JP2007557120A patent/JP5738509B2/ja not_active Expired - Lifetime
- 2006-02-22 ES ES06720975T patent/ES2586412T5/es not_active Expired - Lifetime
- 2006-02-22 KR KR1020147021536A patent/KR20140103356A/ko not_active Ceased
- 2006-02-22 RU RU2007135169/15A patent/RU2404746C2/ru active
- 2006-02-22 AU AU2006216696A patent/AU2006216696B2/en not_active Expired
- 2006-02-22 CA CA2600011A patent/CA2600011C/en not_active Expired - Lifetime
- 2006-02-22 WO PCT/US2006/006252 patent/WO2006091657A1/en not_active Ceased
- 2006-02-22 BR BRPI0608209-2A patent/BRPI0608209A2/pt not_active Application Discontinuation
- 2006-02-22 KR KR1020077021509A patent/KR20070111534A/ko not_active Ceased
- 2006-02-22 CA CA2901244A patent/CA2901244A1/en not_active Abandoned
- 2006-02-22 EP EP06720975.9A patent/EP1848402B2/en not_active Expired - Lifetime
2007
- 2007-06-19 IL IL184033A patent/IL184033A0/en unknown
- 2007-08-15 IS IS8669A patent/IS8669A/is unknown
- 2007-09-21 NO NO20074823A patent/NO20074823L/no not_active Application Discontinuation
2013
- 2013-02-12 JP JP2013024784A patent/JP2013139452A/ja active Pending
2016
- 2016-03-28 IL IL244802A patent/IL244802A/en active IP Right Grant

Also Published As

Publication number	Publication date
JP2008531572A (ja)	2008-08-14
AU2006216696A1 (en)	2006-08-31
EP1848402B2 (en)	2019-02-20
US20060188581A1 (en)	2006-08-24
ES2586412T3 (es)	2016-10-14
KR20180026580A (ko)	2018-03-12
EP1848402B1 (en)	2016-05-11
KR20070111534A (ko)	2007-11-21
MX2007010233A (es)	2007-11-07
IL244802A (en)	2016-08-31
KR20140103356A (ko)	2014-08-26
KR20170023211A (ko)	2017-03-02
AU2006216696B2 (en)	2011-08-18
NO20074823L (no)	2007-11-16
KR20130129300A (ko)	2013-11-27
EP1848402A1 (en)	2007-10-31
US7815942B2 (en)	2010-10-19
ES2586412T5 (es)	2019-05-16
WO2006091657A1 (en)	2006-08-31
NZ560660A (en)	2010-11-26
CA2600011A1 (en)	2006-08-31
HK1103366A1 (zh)	2007-12-21
EP1848402A4 (en)	2012-01-18
IL184033A0 (en)	2007-10-31
JP2013139452A (ja)	2013-07-18
RU2404746C2 (ru)	2010-11-27
IL244802A0 (en)	2016-04-21
CA2901244A1 (en)	2006-08-31
RU2007135169A (ru)	2009-03-27
CA2600011C (en)	2015-11-10
BRPI0608209A2 (pt)	2010-11-09
JP5738509B2 (ja)	2015-06-24

Publication	Publication Date	Title
TWI348710B (en)	2011-09-11	Conductive compositions and processes for use in the manufacture of semiconductor devices
IL244802A0 (en)	2016-04-21	Rasagiline formulations with improved content uniformity
ATE482618T1 (de)	2010-10-15	Wirkstoffkombinationen
ATE444748T1 (de)	2009-10-15	1-ä(3-hydroxy-adamant-1-ylamino)-acetylü- pyrrolidin-2(s)-carbonitril-formulierung mit modifizierter freisetzung
IL188102A0 (en)	2008-03-20	Self-buffering protein formulations
ATE484194T1 (de)	2010-10-15	Wirkstoffkombinationen
EP1876157A4 (en)	2011-10-26	SEMICONDUCTOR PORCELAIN COMPOSITION AND METHOD FOR MANUFACTURING THE SAME
PL1883665T3 (pl)	2018-05-30	Kompozycje polilaktydowe i ich zastosowania
ZA200802272B (en)	2009-01-28	Novel dosage formulation
IL184111A0 (en)	2007-10-31	Prostaglandin-containing compositions and methods for enhancing the stability thereof
IL184834A0 (en)	2007-12-03	Compositions and methods for the manufacture thereof
EP1941901A4 (en)	2009-08-05	TOPICALLY APPLIED FORMULATION AND ITS PREPARATION METHOD AND USES
TWI370809B (en)	2012-08-21	Polyacene and semiconductor formulation
ZA200801896B (en)	2009-09-30	Slow-release composition, method for the preparation thereof, and use of the same
ZA200802646B (en)	2009-09-30	Formulation of AICA Riboside
IL185723A0 (en)	2008-01-06	Controlled release pharmaceutical compositions of liothyronine and methods of making and using the same
GB0507208D0 (en)	2005-05-18	Anti-inflammatory formulation
IL189541A0 (en)	2008-08-07	Stable solid formulation of sertindole
GB0526419D0 (en)	2006-02-08	Formulation
GB0517673D0 (en)	2005-10-05	Formulation
GB0504924D0 (en)	2005-04-20	Perfume compositions
GB0723011D0 (en)	2008-01-02	Fragrance compositions
GB0519437D0 (en)	2005-11-02	Perfume compositions
EP1897932A4 (en)	2013-02-06	FRAGRANCE COMPOSITION
GB0512715D0 (en)	2005-07-27	Fragrance compositions